在妊娠加剧的高血压中激活矿物质皮质类受体突变
D S Geller1, A Farhi, N Pinkerton
1Howard Hughes Medical Institute, Department of Genetics, Yale University School of Medicine, Boyer Center for Molecular Medicine, Room 154, 295 Congress Avenue, New Haven, CT 06510, USA.
概括
一种矿物质皮质体受体 (MR) 突变,S810L,导致早期高血压,在怀孕期间恶化. 这一发现揭示了高血压的新机制,并提供了对核激素受体激活的见解.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 高血压和与怀孕相关的高血压是不清楚起源的重大公共卫生问题.
- 矿物质皮质醇受体 (MR) 在血压调节中起着至关重要的作用.
研究的目的:
- 研究一种特定的矿物质皮质体受体 (MR) 突变S810L在引起高血压方面的作用.
- 阐明S810L突变对MR活性和类固醇结合的影响背后的分子机制.
主要方法:
- 基因分析以确定高血压患者的S810L突变.
- 生物化学测试以评估突变MR的构成性活动和改变的特异性.
- 结构研究 (X射线结晶学),以确定突变效应的分子基础.
主要成果:
- S810L突变导致构成性MR活性,导致早期出现的高血压.
- 孕激素和其他缺乏21-基群的类固醇由于突变而成为MR激动剂,与野生型受体不同.
- 结构分析揭示了突变MR中螺旋5和螺旋3之间的新型范德瓦尔斯相互作用,绕过了对类固醇21基群相互作用的需求.
结论:
- S810L MR突变是一种新的高血压病因,在怀孕期间特别严重.
- 突变通过创建一个新的相互作用表面来改变MR功能,从而导致功能获取.
- 已确定的螺旋5-螺旋3相互作用机制可能是核激素受体激活的一般途径.
相关概念视频
Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Alterations in Blood Pressure
Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart beats)...
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart beats)...
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...


